Onesource Specialty Pharma Limited has informed the Exchange about General Updates
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma has submitted reports from its Audit Committee and Independent Directors confirming that it has compensated the shareholders of Strides Pharma Science who were eligible for fractional shares of Onesource under the Scheme of Arrangement amongst Strides, Steriscience Specialties, and Onesource. The fractional shares were aggregated and held by Catalyst Trusteeship Limited (appointed as trustee on November 26, 2024), who sold them in the market on February 24, 2025 at Rs. 1,275.04 per share (gross), within the 90-day SEBI deadline. The net sale proceeds, after deducting expenses and applicable tax, were distributed to eligible Strides shareholders in proportion to their fractional entitlements, as required under Clause 11.4 of the Scheme and SEBI's Master Circular dated June 20, 2023.
This is a routine regulatory compliance update confirming that eligible Strides shareholders have received cash compensation for fractional Onesource shares they were entitled to under the demerger scheme. It has no direct impact on Onesource's stock price but completes a key post-scheme obligation, providing closure to fractional entitlement matters for Strides shareholders.